Keeping an M&A score? Here's the Big Pharma lineup, pre-megadeal

With so much M&A in the air, the lineup of top pharma companies will no doubt rearrange. Pfizer ($PFE), for one, would regain the No. 1 spot if it succeeds in buying AstraZeneca ($AZN). Merck's ($MRK) consumer health deal and planned drug-brand sale, GlaxoSmithKline ($GSK) and Novartis' ($NVS) swap-and-shop--they'll all force a market-value shuffle. So just for the record, which are the top drugmakers by market value today? Johnson & Johnson ($JNJ) ($282.9 billion), Roche ($RHHBY) ($244.6 billion) and Novartis ($214.5 billion). Pfizer comes in fourth, with $191.2 billion. Report

Suggested Articles

UnitedHealthcare will stop covering Descovy in PrEP in favor of Truvada, which is on track to see low-cost generic competition in September.

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.

Rapper, actress and producer Queen Latifah—whose mother died of sclerosis-associated lung disease—joined Boehringer's "More than Scleroderma” push.